Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith T Flaherty

Showing results (31-40 of 418) with videos related to

Pageof 42
Sort By:
Trends in Cancer|July 26, 2017
Biomarkers in Melanoma: Lessons from Translational MedicineElizabeth I Buchbinder, Keith T Flaherty
Nature Reviews. Clinical Oncology|November 29, 2017
Melanoma in 2017: Moving treatments earlier to move further forwardsMichael A Davies, Keith T Flaherty
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2017
<i>AACR Cancer Progress Report 2017:</i> Harnessing Research Discoveries to Save LivesMarlowe S Tessmer, Keith T Flaherty
European Journal of Cancer (Oxford, England : 1990)|January 8, 2013
Resistance to BRAF-targeted therapy in melanomaRyan J Sullivan, Keith T Flaherty
Current Oncology Reports|March 2, 2006
Her-2 targeted therapy: beyond breast cancer and trastuzumabKeith T Flaherty, Marcia S Brose
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2009
Sorafenib-Related Hand-Foot Skin Reaction Improves, Not Worsens, with Continued TreatmentKeith T Flaherty, Marcia S Brose
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2018
Response to Immune Checkpoint Antibodies: Not All Responses Are Created EqualJustine V Cohen, Keith T Flaherty
Nature Reviews. Clinical Oncology|September 30, 2015
Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanomaRyan J Sullivan, Keith T Flaherty
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2015
Pembrolizumab for Treatment of Patients with Advanced or Unresectable MelanomaRyan J Sullivan, Keith T Flaherty
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2015
New strategies in melanoma: entering the era of combinatorial therapyRyan J Sullivan, Keith T Flaherty
Pageof 42

Showing results (31-40 of 418) with videos related to

Sort By:
Pageof 42
Trends in Cancer|July 26, 2017
Biomarkers in Melanoma: Lessons from Translational MedicineElizabeth I Buchbinder, Keith T Flaherty
Nature Reviews. Clinical Oncology|November 29, 2017
Melanoma in 2017: Moving treatments earlier to move further forwardsMichael A Davies, Keith T Flaherty
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2017
<i>AACR Cancer Progress Report 2017:</i> Harnessing Research Discoveries to Save LivesMarlowe S Tessmer, Keith T Flaherty
European Journal of Cancer (Oxford, England : 1990)|January 8, 2013
Resistance to BRAF-targeted therapy in melanomaRyan J Sullivan, Keith T Flaherty
Current Oncology Reports|March 2, 2006
Her-2 targeted therapy: beyond breast cancer and trastuzumabKeith T Flaherty, Marcia S Brose
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2009
Sorafenib-Related Hand-Foot Skin Reaction Improves, Not Worsens, with Continued TreatmentKeith T Flaherty, Marcia S Brose
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2018
Response to Immune Checkpoint Antibodies: Not All Responses Are Created EqualJustine V Cohen, Keith T Flaherty
Nature Reviews. Clinical Oncology|September 30, 2015
Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanomaRyan J Sullivan, Keith T Flaherty
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2015
Pembrolizumab for Treatment of Patients with Advanced or Unresectable MelanomaRyan J Sullivan, Keith T Flaherty
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2015
New strategies in melanoma: entering the era of combinatorial therapyRyan J Sullivan, Keith T Flaherty
Pageof 42